
Addison’s Disease Market Trends
Addison’s Disease Market Research Report by Diagnosis (Laboratory Testing and Imaging Tests), Treatment (Oral Corticosteroid and Corticosteroid Injections), End User (Hospitals and Clinics, Diagnostic Laboratories, and Others)-Forecast till 2035

Market Summary
The Global Addison's Disease Market is projected to experience substantial growth from 2.34 USD Billion in 2024 to 7.29 USD Billion by 2035.
Key Market Trends & Highlights
Addison's Disease Key Trends and Highlights
- The market is expected to grow at a compound annual growth rate of 10.88% from 2025 to 2035.
- By 2035, the market valuation is anticipated to reach 7.29 USD Billion, indicating robust expansion.
- In 2024, the market is valued at 2.34 USD Billion, laying a strong foundation for future growth.
- Growing adoption of innovative treatment options due to increasing awareness of Addison's Disease is a major market driver.
Market Size & Forecast
2024 Market Size | 2.34 (USD Billion) |
2035 Market Size | 7.29 (USD Billion) |
CAGR (2025-2035) | 10.88% |
Largest Regional Market Share in 2024 | latin_america) |
Major Players
Pfizer Inc, Boehringer Ingelheim International GmbH, Shire, Tocris Bioscience, GlaxoSmithKline plc, Merck KGaA, Lupin Pharmaceuticals, Inc, Abbott, Amgen Limited & Amgen Ireland Limited, Bayer AG, Biogen, Eli Lilly and Company, Novartis AG, Diurnal, Switzer Life science Pvt. Ltd
Market Trends
The increasing awareness and diagnosis of Addison's disease, coupled with advancements in treatment options, appear to be driving a notable shift in the management of this rare endocrine disorder.
National Institutes of Health (NIH)
Addison’s Disease Market Market Drivers
Market Growth Chart
Development of Targeted Therapies
The emergence of targeted therapies is reshaping the Global Addison's Disease Market Industry. Pharmaceutical companies are increasingly focusing on developing medications that specifically address the hormonal deficiencies associated with Addison's disease. These targeted treatments aim to improve patient outcomes by providing more effective management of symptoms. As research progresses, new therapies are expected to enter the market, potentially increasing the overall market size. By 2035, the market is anticipated to reach 7.29 USD Billion, driven by the introduction of innovative treatment options that cater to the unique needs of Addison's disease patients.
Advancements in Diagnostic Techniques
Innovations in diagnostic methodologies are significantly impacting the Global Addison's Disease Market Industry. Enhanced imaging techniques and hormonal assays facilitate earlier and more accurate diagnosis of Addison's disease. For instance, the introduction of advanced blood tests allows for the precise measurement of cortisol levels, leading to timely intervention. As diagnostic capabilities improve, healthcare providers can identify patients sooner, which may lead to better management of the disease. This trend is likely to contribute to the market's growth, as early diagnosis correlates with improved patient outcomes and increased demand for treatment options.
Rising Prevalence of Addison's Disease
The Global Addison's Disease Market Industry is experiencing growth due to the increasing prevalence of Addison's disease. This condition, characterized by insufficient production of adrenal hormones, affects approximately 60 to 100 individuals per million globally. As awareness of this rare disorder rises, more patients are being diagnosed, contributing to market expansion. The growing number of diagnosed cases is expected to drive demand for treatment options, thereby enhancing the market's value. In 2024, the market is projected to reach 2.34 USD Billion, reflecting the urgent need for effective therapies and management strategies.
Growing Awareness and Education Initiatives
The Global Addison's Disease Market Industry benefits from increased awareness and educational initiatives aimed at both healthcare professionals and the general public. Organizations and advocacy groups are actively promoting information about Addison's disease, its symptoms, and treatment options. This heightened awareness encourages individuals experiencing symptoms to seek medical attention, leading to more diagnoses. As a result, the market is likely to see an uptick in demand for therapies and management solutions. The ongoing education efforts are crucial in fostering a better understanding of the disease, which may ultimately enhance patient care and treatment adherence.
Increased Investment in Healthcare Infrastructure
Investment in healthcare infrastructure is a critical driver for the Global Addison's Disease Market Industry. Governments and private entities are allocating resources to enhance healthcare facilities, improve access to care, and support research initiatives. This investment is particularly vital in regions where healthcare access is limited, as it enables better diagnosis and treatment of Addison's disease. Improved healthcare infrastructure can lead to a more robust supply chain for medications and therapies, ultimately benefiting patients. As healthcare systems evolve, the market is likely to experience growth, reflecting the positive impact of these investments on patient care.
Market Segment Insights
Regional Insights
Key Companies in the Addison’s Disease Market market include





Industry Developments
Lupin Ltd (Lupin) is a pharmaceutical company that produces and markets generic and branded pharmaceuticals, as well as active pharmaceutical ingredients (APIs). Cardiovascular, diabetes etc are all part of the company's product range. Oral, ophthalmic, dermatological, and inhalation product research are key priorities for the organization. The company's operations are reported under a single segment, Pharmaceuticals. Formulations, active pharmaceutical ingredients (APIs), generic formulations, and biotechnology products are all part of Lupin's business.
In August 2015, Amgen, a biotechnology corporation located in the United States, launched its significantly enlarged production plant in Dun Laoghaire, Ireland. The $300 million expansion expanded manufacturing facilities to the existing factory, enhancing its capabilities and positioning it as a major hub for Amgen's global operations. The move was part of Amgen's long-term plan to manufacture all of its pharmaceuticals at the Dun Laoghaire facility, ensuring a steady supply of Amgen's medicines for severely sick patients across the world.
Global Addison’s Disease Market, by Diagnosis
-
Laboratory Tests
- Blood Tests
- ACTH Stimulation Tests
- Insulin-Induced Hypoglycemia Test
- Other Tests
-
Imaging Tests
- Chest Radiography
- CT Scan
Global Addison’s Disease Market, by Treatment
- Oral Corticosteroid
- Corticosteroid Injections
Global Addison’s Disease Market, by End User
- Hospitals and Clinics
- Diagnostic Laboratories
- Other End Users
Global Addison’s Disease Market, by Region
-
Americas
- North America
- US
- Canada
- North America
- South America
-
Europe
-
Western Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Western Europe
-
Western Europe
- Eastern Europe
-
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
-
Middle East & Africa
- Middle East
- Africa
Global Addison’s Disease Market, by Key Players
- Pfizer Inc.
- Boehringer Ingelheim International GmbH
- Shire
- Tocris Bioscience
- GlaxoSmithKline Plc
- Merck KGaA
- Lupin Pharmaceuticals, Inc.
- Abbott
- Amgen Limited & Amgen Ireland Limited
Future Outlook
Addison’s Disease Market Future Outlook
The Global Addison's Disease Market is projected to grow at a 10.88% CAGR from 2024 to 2035, driven by increasing awareness, advancements in treatment options, and rising prevalence rates.
New opportunities lie in:
- Develop innovative therapies targeting adrenal insufficiency to enhance patient outcomes.
- Leverage telemedicine for remote monitoring and management of Addison's Disease patients.
- Invest in educational campaigns to raise awareness and improve early diagnosis rates.
By 2035, the Addison's Disease Market is expected to exhibit robust growth, reflecting advancements in treatment and increased patient engagement.
Market Segmentation
Report Scope
Report Attribute/Metric | Details |
Market Size | USD 5.35 Billion |
CAGR | 2024-2032:10.84% |
Base Year | 2023 |
Forecast Period | 2032 |
Historical Data | 2018 |
Forecast Units | Value (USD Billion) |
Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered | Diagnosis, Treatment And End User |
Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
Key Vendors | Pfizer Inc., Boehringer Ingelheim International GmbH, Shire, Tocris Bioscience, GlaxoSmithKline plc, Merck KGaA, Lupin Pharmaceuticals, Inc., Abbott, Amgen Limited & Amgen Ireland Limited, Bayer AG, Biogen, Eli Lilly and Company, Novartis AG, Diurnal, Switzer Life science Pvt. Ltd |
Key Market Opportunities | R&D Activities |
Key Market Drivers | · Growing prevalence of Addison’s disease · Increasing awareness of the disease · Rising healthcare expenditure |
Market Highlights
Author
Latest Comments
This is a great article! Really helped me understand the topic better.
Thanks for sharing this. I’ve bookmarked it for later reference.
FAQs
At what CAGR is the Addison’s disease market projected to grow during the forecast period?
The Addison’s disease market is projected to grow at a 10.84% CAGR between 2024-2032.
Which region is projected to command the largest share in the Addison’s disease market?
North America is projected to command the largest share in the Addison’s disease market.
Which treatment segment will dominate the Addison’s disease market?
Oral corticosteroids segment will dominate the Addison’s disease market.
What are the key factors driving the Addison’s disease market?
Rising healthcare expenditure and growing awareness about the disease is boosting market growth.
Which factors may limit Addison’s disease market growth?
Inability to diagnose Addison’s disease may limit market growth.
-
Table of Contents
-
Chapter 1. Report Prologue
-
Chapter 2. Market Introduction
- Definition
-
Scope of the Study
- Research Objective
- Assumptions
- Limitations
-
Chapter 3. Research Methodology
- Introduction
- Primary Research
- Secondary Research
- Market Size Estimation
-
Chapter 4. Market Dynamics
- Drivers
- Restraints
- Opportunities
- Challenges
- Macroeconomic Indicators
- Technology Trends & Assessment
-
Chapter 5. Market Factor Analysis
-
Porter’s Five Forces Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of New Entrants
- Threat of Substitutes
- Intensity of Rivalry
- Value Chain Analysis
- Investment Feasibility Analysis
- Pricing Analysis
-
Porter’s Five Forces Analysis
-
Chapter 6. Global Addison’s Disease Market, by Diagnosis
- Introduction
- Laboratory Testing
-
6.2.1 Blood Tests
-
Market Estimates & Forecast, by Region, 2020–2027
-
Market Estimates & Forecast, by Country, 2020–2027
-
6.2.2 ACTH Stimulation Test
-
Market Estimates & Forecast, by Region, 2020–2027
-
Market Estimates & Forecast, by Country, 2020–2027
-
6.2.3 Insulin-Induced Hypoglycemia test
-
Market Estimates & Forecast, by Region, 2020–2027
-
Market Estimates & Forecast, by Country, 2020–2027
-
6.2.4 Other Tests
- Imaging Tests
-
6.3.1 Chest Radiography
-
Market Estimates & Forecast, by Region, 2020–2027
-
Market Estimates & Forecast, by Country, 2020–2027
- CT Scan
-
Market Estimates & Forecast, by Region, 2020–2027
-
Market Estimates & Forecast, by Country, 2020–2027
-
Chapter 7. Global Addison’s Disease Market, by Treatment
- Introduction
- Oral Corticosteroids
- Corticosteroid Injections
-
Market Estimates & Forecast, by Country, 2020–2027
-
Chapter 8. Global Addison’s Disease Market, by End User
- Introduction
- Hospitals and Clinics
-
Market Estimates & Forecast, by Region, 2020–2027
-
Market Estimates & Forecast, by Country, 2020–2027
- Diagnostic Laboratories
-
Market Estimates & Forecast, by Country, 2020–2027
- Other End Users
-
Market Estimates & Forecast, by Country, 2020–2027
-
Chapter 9. Global Addison’s Disease Market, by Region
- Introduction
-
Americas
- North America
- South America
-
Europe
- Western Europe
- Eastern Europe
-
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
-
Middle East & Africa
- Middle East
- Africa
-
Chapter 10. Company Landscape
- Introduction
- Market Share Analysis
- Key Development & Strategies
-
Chapter 11. Company Profiles
-
Pfizer Inc.
- Company Overview
- Product Overview
- Financials Overview
- Key Developments
- SWOT Analysis
-
Boehringer Ingelheim International GmbH
- Company Overview
- Product Overview
- Financial Overview
- Key Developments
- SWOT Analysis
-
Shire
- Company Overview
- Product Overview
- Financial Overview
- Key Development
- SWOT Analysis
-
Tocris Bioscience
- Company Overview
- Product Overview
- Financial Overview
- Key Development
- SWOT Analysis
-
GlaxoSmithKline plc
- Company Overview
- Product Overview
- Financial overview
- Key Developments
- SWOT Analysis
-
Merck KGaA
- Company Overview
- Product Overview
- Financial Overview
- Key Developments
- SWOT Analysis
-
Lupin Pharmaceuticals, Inc.
- Overview
- Product Overview
- Financial Overview
- Key Developments
- SWOT Analysis
-
Abbott
- Overview
- Product Overview
- Financials
- Key Developments
- SWOT Analysis
-
Amgen Limited & Amgen Ireland Limited
- Overview
- Product Overview
- Financials
- Key Developments
- SWOT Analysis
-
Bayer AG
- Overview
- Product Overview
- Financials
- Key Developments
- SWOT Analysis
-
Biogen
- Overview
- Product Overview
- Financials
- Key Developments
- SWOT Analysis
-
Eli Lilly and Company
- Overview
- Product Overview
- Financials
- Key Developments
- SWOT Analysis
-
Novartis AG
- Overview
- Product Overview
- Financials
- Key Developments
- SWOT Analysis
-
Diurnal
- Overview
- Product Overview
- Financials
- Key Developments
- SWOT Analysis
-
Switzer Life science Pvt. Ltd.
- Overview
- Product Overview
- Financials
- Key Developments
- SWOT Analysis
-
Pfizer Inc.
-
Chapter 12 MRFR Conclusion
-
Key Findings
- From CEO’s Viewpoint
- Unmet Needs of the Market
- Key Companies to Watch
- Predictions for the Addison’s Disease Industry
-
Key Findings
-
Chapter 13. Appendix
-
List of Tables and Figures
- LIST OF TABLES
- Table 1 Global Addison’s Disease Market Synopsis, 2020–2027
- Table 2 Global Addison’s Disease Market Estimates and Forecast, 2020–2027 (USD Million)
- Table 3 Global Addison’s Disease Market, by Region, 2020–2027 (USD Million)
- Table 4 Global Addison’s Disease Market, by Diagnosis, 2020–2027 (USD Million)
- Table 5 Global Addison’s Disease Market, by Treatment, 2020–2027 (USD Million)
- Table 6 Global Addison’s Disease Market, by End User, 2020–2027 (USD Million)
- Table 7 North America: Addison’s Disease Market, by Diagnosis, 2020–2027 (USD Million)
- Table 8 North America: Addison’s Disease Market, by Treatment, 2020–2027 (USD Million)
- Table 9 North America: Addison’s Disease Market, by End User, 2020–2027 (USD Million)
- Table 10 US: Addison’s Disease Market, by Diagnosis, 2020–2027 (USD Million)
- Table 11 US: Addison’s Disease Market, by Treatment, 2020–2027 (USD Million)
- Table 12 US: Addison’s Disease Market, by End User, 2020–2027 (USD Million)
- Table 13 Canada: Addison’s Disease Market, by Diagnosis, 2020–2027 (USD Million)
- Table 14 Canada: Addison’s Disease Market, by Treatment, 2020–2027 (USD Million)
- Table 15 Canada: Addison’s Disease Market, by End User, 2020–2027 (USD Million)
- Table 16 South America: Addison’s Disease Market, by Diagnosis, 2020–2027 (USD Million)
- Table 17 South America: Addison’s Disease Market, by Treatment, 2020–2027 (USD Million)
- Table 18 South America: Addison’s Disease Market, by End User, 2020–2027 (USD Million)
- Table 19 Europe: Addison’s Disease Market, by Diagnosis, 2020–2027 (USD Million)
- Table 20 Europe: Addison’s Disease Market, by Treatment, 2020–2027 (USD Million)
- Table 21 Europe: Addison’s Disease Market, by End User, 2020–2027 (USD Million)
- Table 22 Western Europe: Addison’s Disease Market, by Diagnosis, 2020– 2027 (USD Million)
- Table 23 Western Europe: Addison’s Disease Market, by Treatment, 2020– 2027 (USD Million)
- Table 24 Western Europe: Addison’s Disease Market, by End User, 2020–2027 (USD Million)
- Table 25 Eastern Europe: Addison’s Disease Market, by Diagnosis, 2020– 2027 (USD Million)
- Table 26 Eastern Europe: Addison’s Disease Market, by Treatment, 2020–2027 (USD Million)
- Table 27 Eastern Europe: Addison’s Disease Market, by End User, 2020–2027 (USD Million)
- Table 28 Asia-Pacific: Addison’s Disease Market, by Diagnosis, 2020–2027 (USD Million)
- Table 29 Asia-Pacific: Addison’s Disease Market, by Treatment, 2020–2027 (USD Million)
- Table 30 Asia-Pacific: Addison’s Disease Market, by End User, 2020–2027 (USD Million)
- Table 31 Middle East & Africa: Addison’s Disease Market, by Diagnosis, 2020–2027 (USD Million)
- Table 32 Middle East & Africa: Addison’s Disease Market, by Treatment, 2020– 2027 (USD Million)
- Table 33 Middle East & Africa: Addison’s Disease Market, by End User, 2020– 2027 (USD Million) LIST OF FIGURES
- Figure 1 Research Process
- Figure 2 Segmentation for Global Addison’s Disease Market
- Figure 3 Segmentation Market Dynamics for Global Addison’s Disease Market
- Figure 4 Global Addison’s Disease Market Share, by Diagnosis, 2020
- Figure 5 Global Addison’s Disease Market Share, by Treatment, 2020
- Figure 6 Global Addison’s Disease Market Share, by End User, 2020
- Figure 7 Global Addison’s Disease Market Share, by Region, 2020
- Figure 8 North America: Addison’s Disease Market Share, by Country, 2020
- Figure 9 Europe: Addison’s Disease Market Share, by Country, 2020
- Figure 10 Asia-Pacific: Addison’s Disease Market Share, by Country, 2020
- Figure 11 Middle East & Africa: Addison’s Disease Market Share, by Country, 201
- Figure 12 Global Addison’s Disease Market: Company Share Analysis, 2020 (%)
- Figure 13 Pfizer Inc.: Key Financials
- Figure 14 Pfizer Inc.: Segmental Revenue
- Figure 15 Pfizer Inc.: Geographical Revenue
- Figure 16 Boehringer Ingelheim International GmbH: Key Financials
- Figure 17 Boehringer Ingelheim International GmbH: Segmental Revenue
- Figure 18 Boehringer Ingelheim International GmbH: Geographical Revenue
- Figure 19 Shire: Key Financials
- Figure 20 Shire: Segmental Revenue
- Figure 21 Shire: Geographical Revenue
- Figure 22 Tocris Bioscience: Key Financials
- Figure 23 Tocris Bioscience: Segmental Revenue
- Figure 24 Tocris Bioscience: Geographical Revenue
- Figure 25 GlaxoSmithKline Plc: Key Financials
- Figure 26 GlaxoSmithKline Plc: Segmental Revenue
- Figure 27 GlaxoSmithKline Plc. Geographical Revenue
- Figure 28 Merck KGaA : Key Financials
- Figure 29 Merck KGaA : Segmental Revenue
- Figure 30 Merck KGaA : Geographical Revenue
- Figure 31 Lupin Pharmaceuticals, Inc.: Key Financials
- Figure 32 Lupin Pharmaceuticals, Inc.: Segmental Revenue
- Figure 33 Lupin Pharmaceuticals, Inc.: Geographical Revenue
- Figure 34 Abbott: Key Financials
- Figure 35 Abbott: Segmental Revenue
- Figure 36 Abbott: Geographical Revenue
- Figure 37 Amgen Limited & Amgen Ireland Limited: Key Financials
- Figure 38 Amgen Limited & Amgen Ireland Limited: Segmental Revenue
- Figure 39 Amgen Limited & Amgen Ireland Limited: Geographical Revenue
- Figure 40 Bayer AG: Key Financials
- Figure 41 Bayer AG: Segmental Revenue
- Figure 42 Bayer AG: Geographical Revenue
- Figure 43 Biogen: Key Financials
- Figure 44 Biogen: Segmental Revenue
- Figure 45 Biogen: Geographical Revenue
- Figure 46 Eli Lilly and Company: Key Financials
- Figure 47 Eli Lilly and Company: Segmental Revenue
- Figure 48 Eli Lilly and Company: Geographical Revenue
- Figure 49 Novartis AG: Key Financials
- Figure 50 Novartis AG: Segmental Revenue
- Figure 51 Novartis AG: Geographical Revenue
- Figure 52 Diurnal: Key Financials
- Figure 53 Diurnal: Segmental Revenue
- Figure 54 Diurnal: Geographical Revenue
- Figure 55 Switzer Life science Pvt. Ltd.: Key Financials
- Figure 56 Switzer Life science Pvt. Ltd.: Segmental Revenue
- Figure 57 Switzer Life science Pvt. Ltd.: Geographical Revenue
Addison’s Disease Market Segmentation
Market Segmentation Overview
- Detailed segmentation data will be available in the full report
- Comprehensive analysis by multiple parameters
- Regional and country-level breakdowns
- Market size forecasts by segment

Free Sample Request
Kindly complete the form below to receive a free sample of this Report
Customer Strories
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”
Leave a Comment